SCHEMBL1463711

SCHEMBL1463711

Brc1ccc2[nH]c(C3CCCCC3)cc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.42
IDO1 P14902 1/20 0.39
AHR P35869 2/20 0.38
CYP2A6 P11509 1/20 0.38
NR4A2 P43354 1/20 0.38
CCNA2 P20248 2/20 0.37
CDK2 P24941 2/20 0.37
CCNA1 P78396 2/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
CHEK1 O14757 1/20 0.36
NOS1 P29475 1/20 0.36
METAP2 P50579 1/20 0.36
CSNK2A1 P68400 1/20 0.36
FLT3 P36888 1/20 0.35
DAO P14920 1/20 0.35
MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20740536 0.98 CYP19A1 (0.44) CYP19A1IDO1AHRCYP2A6NR4A2
SCHEMBL24906160 0.80 KDM4E (0.50) CYP2A6MEN1KMT2AHRH4DAO
SCHEMBL10441226 0.77 AOC3 (0.42) CYP2A6FLT3NPC1RAB9AKDM4E
SCHEMBL1980228 0.77 HRH4 (0.47) CYP19A1IDO1MEN1POLBKMT2A
SCHEMBL17212669 0.76 LMNA (0.54) CDK2KMT2ACHEK1METAP2FLT3
SCHEMBL3640169 0.75 AOC3 (0.44) CYP2A6FLT3MAPTNPC1RAB9A
SCHEMBL15751009 0.74 NPY5R (0.40) CCNA2CDK2CCNA1MEN1POLB
SCHEMBL2124303 0.74 HSP90AA1 (0.50) CYP19A1MEN1POLBKMT2AHRH4
SCHEMBL15971257 0.73 KMO (0.45) CCNA2CDK2CCNA1KMT2AHRH3
Tert-Butyl Formate SCHEMBL27878459 0.72 PLAT (0.37) CYP19A1MEN1POLBKMT2AHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102574788-A Indole derivatives as crac modulators HOFFMANN LA ROCHE 2012-07-11 CN disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ORAI1, RYR2, CACNA1E CYP19A1 1576/4885IDO1 135/4885AHR 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.